Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07209215) titled 'ctDNA-Informed Management of Early-Stage Rectal Cancer' on Sept. 30.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of California, Davis
Condition:
Rectal Adenocarcinoma
Rectal Cancer
Early-stage Rectal Cancer
Locally Advanced Rectal Adenocarcinoma
Intervention:
Drug: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: November 2025
Target Sample Size: 2...